Hippocampal subfield volumetry in corticobasal syndrome of diverse underlying pathologies.
Alzheimer’s disease
Cerebrospinal fluid biomarkers
Corticobasal syndrome
Hippocampal subfields
Hippocampus
MRI
Volumetry
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
13
11
2022
accepted:
15
12
2022
revised:
14
12
2022
pubmed:
25
12
2022
medline:
22
3
2023
entrez:
24
12
2022
Statut:
ppublish
Résumé
Multiple pathologies may underlie corticobasal syndrome (CBS), including Alzheimer's disease (AD). Typical amnestic AD is characterized by early selective hippocampal atrophy. The profile of hippocampal atrophy in AD patients presenting as CBS (CBS-AD), compared to CBS patients of non-AD pathologies (CBS-nAD) and amnestic AD patients, has not been studied. To compare hippocampal subfield atrophy patterns between CBS-AD, CBS-nAD, typical amnestic AD patients, and control subjects. Automated hippocampal subfield volumetry was performed via the hippocampal subfield segmentation pipeline of Freesurfer 6.0 on 3D T1-weighted images. CBS patients were classified as CBS-AD or CBS-nAD based on CSF AD biomarkers by applying the AT(N) classification system. Mean volumes of nine hippocampal subfields, head-body-tail segments, total hippocampus, and entorhinal and parahippocampal gyrus cortical thickness were measured. Eighty-three subjects were included (CBS-AD: n = 14; CBS-nAD: n = 17; amnestic AD: n = 29; controls: n = 23). CBS-AD patients had greater whole hippocampal and hippocampal subfield atrophy compared to CBS-nAD. CBS-AD and amnestic AD patients did not differ in subfield volumes. CBS-nAD did not exhibit hippocampal atrophy compared to controls, with the exception of fimbria. (Cohen's d = 1.27; p = 0.038). Presubiculum (Cohen's d = 1.00; p = 0.002) and hippocampal body (Cohen's d = 0.95; p = 0.001) volumes exhibited the greatest differences between CBS-AD and CBS-nAD. Hippocampal subfield volume provided combined sensitivity and specificity < 80% for the discrimination of CBS-AD from CBS-nAD. CBS-AD and amnestic AD patients exhibit comparable, and significantly greater hippocampal atrophy compared to CBS-nAD patients. Hippocampal subfield volumetry in CBS is indicative of an AD underlying pathology.
Identifiants
pubmed: 36565349
doi: 10.1007/s00415-022-11538-5
pii: 10.1007/s00415-022-11538-5
doi:
Substances chimiques
NAD
0U46U6E8UK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2059-2068Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Troster AI, Vidailhet M, Weiner WJ (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80:496–503
doi: 10.1212/WNL.0b013e31827f0fd1
pubmed: 23359374
pmcid: 3590050
Armstrong RA, Cairns NJ, Lantos PL (2000) A quantitative study of the pathological lesions in the neocortex and hippocampus of twelve patients with corticobasal degeneration. Exp Neurol 163:348–356
doi: 10.1006/exnr.2000.7392
pubmed: 10833308
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259
doi: 10.1007/BF00308809
pubmed: 1759558
Canto CB, Wouterlood FG, Witter MP (2008) What does the anatomical organization of the entorhinal cortex tell us? Neural Plast 2008:381243
doi: 10.1155/2008/381243
pubmed: 18769556
pmcid: 2526269
Chand P, Grafman J, Dickson D, Ishizawa K, Litvan I (2006) Alzheimer’s disease presenting as corticobasal syndrome. Mov Disord 21:2018–2022
doi: 10.1002/mds.21055
pubmed: 16977625
Constantinides VC, Paraskevas GP, Boufidou F, Bourbouli M, Stefanis L, Kapaki E (2021) Cerebrospinal fluid biomarker profiling in corticobasal degeneration: application of the AT(N) and other classification systems. Parkinsonism Relat Disord 82:44–49
doi: 10.1016/j.parkreldis.2020.11.016
pubmed: 33246219
Constantinides VC, Paraskevas GP, Efthymiopoulou E, Stefanis L, Kapaki E (2019) Clinical, neuropsychological and imaging characteristics of Alzheimer’s disease patients presenting as corticobasal syndrome. J Neurol Sci 398:142–147
doi: 10.1016/j.jns.2019.01.046
pubmed: 30711771
del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Saez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med 6:419–430
doi: 10.2217/bmm.12.46
pubmed: 22917144
Doran M, du Plessis DG, Enevoldson TP, Fletcher NA, Ghadiali E, Larner AJ (2003) Pathological heterogeneity of clinically diagnosed corticobasal degeneration. J Neurol Sci 216:127–134
doi: 10.1016/S0022-510X(03)00232-6
pubmed: 14607314
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13:614–629
doi: 10.1016/S1474-4422(14)70090-0
pubmed: 24849862
Eliassen CF, Selnes P, Selseth Almdahl I, Reinvang I, Fladby T, Hessen E (2015) Hippocampal subfield atrophy in multi-domain but not amnestic mild cognitive impairment. Dement Geriatr Cogn Disord 40:44–53
doi: 10.1159/000381142
pubmed: 25924735
Fischl B (2012) FreeSurfer. Neuroimage 62:774–781
doi: 10.1016/j.neuroimage.2012.01.021
pubmed: 22248573
Gabere M, Thu Pham NT, Graff-Radford J, Machulda MM, Duffy JR, Josephs KA, Whitwell JL, Initiative fAsDN (2020) Automated hippocampal subfield volumetric analyses in atypical Alzheimer’s disease. J Alzheimers Dis 78:927–937
doi: 10.3233/JAD-200625
pubmed: 33074228
pmcid: 7732352
Gibb WR, Luthert PJ, Marsden CD (1989) Corticobasal degeneration. Brain 112(Pt 5):1171–1192
doi: 10.1093/brain/112.5.1171
pubmed: 2478251
Iglesias JE, Augustinack JC, Nguyen K, Player CM, Player A, Wright M, Roy N, Frosch MP, McKee AC, Wald LL, Fischl B, Van Leemput K, Alzheimer’s Disease Neuroimaging I (2015) A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: application to adaptive segmentation of in vivo MRI. Neuroimage 115:117–137
doi: 10.1016/j.neuroimage.2015.04.042
pubmed: 25936807
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14:535–562
doi: 10.1016/j.jalz.2018.02.018
pubmed: 29653606
pmcid: 5958625
Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128
doi: 10.1016/S1474-4422(09)70299-6
pubmed: 20083042
pmcid: 2819840
Josephs KA, Whitwell JL, Boeve BF, Knopman DS, Petersen RC, Hu WT, Parisi JE, Dickson DW, Jack CR Jr (2010) Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer’s disease. Mov Disord 25:1246–1252
doi: 10.1002/mds.23062
pubmed: 20629131
pmcid: 2921765
Jung NY, Lee JH, Lee YM, Shin JH, Shin MJ, Lee MJ, Pak K, Hwang C, Ahn JW, Sung S, Choi KU, Huh GY, Kim EJ (2018) Early stage memory impairment, visual hallucinations, and myoclonus combined with temporal lobe atrophy predict Alzheimer’s disease pathology in corticobasal syndrome. Neurocase 24:145–150
doi: 10.1080/13554794.2018.1494290
pubmed: 29987978
Kłodowska-Duda G, Słowiński J, Opala G, Gorzkowska A, Jasińska-Myga B, Wszołek ZK, Dickson DW (2006) Corticobasal degeneration—clinico-pathological considerations. Folia Neuropathol 44:257–264
pubmed: 17183452
Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ, Huang EJ, Trojanowski JQ, Growdon ME, Jang JY, Sidhu M, See TM, Karydas AM, Gorno-Tempini ML, Boxer AL, Weiner MW, Geschwind MD, Rankin KP, Miller BL (2011) Clinicopathological correlations in corticobasal degeneration. Ann Neurol 70:327–340
doi: 10.1002/ana.22424
pubmed: 21823158
pmcid: 3154081
Ling H, O’Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, Paviour DC, Lees AJ (2010) Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133:2045–2057
doi: 10.1093/brain/awq123
pubmed: 20584946
Malkani RG, Dickson DW, Simuni T (2012) Hippocampal-sparing Alzheimer’s disease presenting as corticobasal syndrome. Parkinsonism Relat Disord 18:683–685
doi: 10.1016/j.parkreldis.2011.11.022
pubmed: 22172552
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269
doi: 10.1016/j.jalz.2011.03.005
pubmed: 21514250
pmcid: 3312024
Murray R, Neumann M, Forman MS, Farmer J, Massimo L, Rice A, Miller BL, Johnson JK, Clark CM, Hurtig HI, Gorno-Tempini ML, Lee VM, Trojanowski JQ, Grossman M (2007) Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 68:1274–1283
doi: 10.1212/01.wnl.0000259519.78480.c3
pubmed: 17438218
Nishida N, Yoshida K, Hata Y, Arai Y, Kinoshita K (2015) Pathological features of preclinical or early clinical stages of corticobasal degeneration: a comparison with advanced cases. Neuropathol Appl Neurobiol 41:893–905
doi: 10.1111/nan.12229
pubmed: 25708668
Phillips JS, Da Re F, Dratch L, Xie SX, Irwin DJ, McMillan CT, Vaishnavi SN, Ferrarese C, Lee EB, Shaw LM, Trojanowski JQ, Wolk DA, Grossman M (2018) Neocortical origin and progression of gray matter atrophy in non-amnestic Alzheimer’s disease. Neurobiol Aging 63:75–87
doi: 10.1016/j.neurobiolaging.2017.11.008
pubmed: 29223682
Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58:1395–1402
doi: 10.1001/archneur.58.9.1395
pubmed: 11559310
Sakae N, Josephs KA, Litvan I, Murray ME, Duara R, Uitti RJ, Wszolek ZK, van Gerpen J, Graff-Radford NR, Dickson DW (2019) Clinicopathologic subtype of Alzheimer’s disease presenting as corticobasal syndrome. Alzheimers Dement 15:1218–1228
doi: 10.1016/j.jalz.2019.04.011
pubmed: 31399334
pmcid: 9262170
Sutherland RJ, Rodriguez AJ (1989) The role of the fornix/fimbria and some related subcortical structures in place learning and memory. Behav Brain Res 32:265–277
doi: 10.1016/S0166-4328(89)80059-2
pubmed: 2496702